Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-24 02:01 | 2025-12-19 | ARWR | Arrowhead Pharmaceuticals Inc. | OLUKOTUN ADEOYE Y | Director | SELL | $67.66 | 10,000 | $676,623 | 33,600 |
| 2025-12-24 02:50 | 2025-12-19 | MIRM | Mirum Pharmaceuticals, Inc. | GREY MICHAEL G | Director | OPT+S | $78.00 | 50,000 | $3,900,000 | 0 |
| 2025-12-24 00:27 | 2025-12-22 | ANAB | AnaptysBio Inc. | LOUMEAU ERIC J | Officer | OPT+S | $51.00 | 10,000 | $510,000 | 8,947 |
| 2025-12-24 00:16 | 2025-12-19 | FOLD | AMICUS THERAPEUTICS, INC. | Clark David Michael | Officer | SELL | $14.17 | 25,642 | $363,380 | 245,690 |
| 2025-12-23 19:28 | 2025-12-23 | GALT | GALECTIN THERAPEUTICS INC | ELDRED KARY | Director | BUY | $3.73 | 700 | $2,611 | 65,382 |
| 2025-12-23 21:19 | 2025-12-23 | GALT | GALECTIN THERAPEUTICS INC | FREEMAN KEVIN D | Director | BUY | $3.55 | 5,500 | $19,514 | 55,269 |
| 2025-12-24 00:33 | 2025-12-23 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $512.12 | 50 | $25,606 | 420 |
| 2025-12-24 00:33 | 2025-12-22 | UTHR | UNITED THERAPEUTICS Corp | SULLIVAN LOUIS W | Director | OPT+S | $512.13 | 5,950 | $3,047,201 | 0 |
| 2025-12-24 01:15 | 2025-12-19 | PTCT | PTC THERAPEUTICS, INC. | Pauwels Eric | Officer | OPT+S | $77.26 | 20,508 | $1,584,350 | 70,373 |
| 2025-12-24 00:13 | 2025-12-22 | CYTK | CYTOKINETICS INC | WIERENGA WENDELL | Director | OPT+S | $66.14 | 20,000 | $1,322,800 | 32,444 |
| 2025-12-23 00:09 | 2025-12-19 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $38.38 | 20,000 | $767,582 | 120,000 |
| 2025-12-22 16:15 | 2025-12-18 | HYPD | HYPERION DEFI, INC. | Strahlman Ellen R | Director | BUY | $3.14 | 38,444 | $120,664 | 95,150 |
| 2025-12-22 15:00 | 2025-12-18 | RNXT | RenovoRx, Inc. | Bagai Shaun | Director, Officer | BUY | $0.90 | 5,000 | $4,507 | 340,040 |
| 2025-12-23 03:45 | 2025-12-18 | BNTC | Benitec Biopharma Inc. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director, 10% owner | BUY | $11.68 | 46,141 | $538,973 | 1,826,653 |
| 2025-12-23 01:52 | 2025-12-22 | ZYME | Zymeworks Inc. | Galbraith Kenneth | Director, Officer | OPT+S | $27.02 | 47,528 | $1,284,311 | 133,275 |
| 2025-12-22 15:07 | 2025-12-19 | EVMN | Evommune, Inc. | Hopfner Robert Lorne | Director, 10% owner | BUY | $17.35 | 1,000 | $17,350 | 4,026 |
| 2025-12-22 15:32 | 2025-12-19 | IMNM | Immunome Inc. | Tsai Philip | Officer | BUY | $20.49 | 10,000 | $204,900 | 43,300 |
| 2025-12-23 01:15 | 2025-12-18 | MRUS | Merus N.V. | GENMAB A/S | 10% owner | BUY | $97.00 | 278,441 | $27,008,777 | 72,013,065 |
| 2025-12-23 00:04 | 2025-12-19 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Mottola Frank | Officer | OPT+S | $50.41 | 20,000 | $1,008,150 | 15,496 |
| 2025-12-23 00:10 | 2025-12-22 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Director | BUY | $4.13 | 12,500 | $51,569 | 12,500 |
| 2025-12-23 00:00 | 2025-12-19 | LITS | Lite Strategy, Inc. | Flynn James P | Director | BUY | $1.40 | 70,000 | $97,699 | 100,000 |
| 2025-12-23 00:15 | 2025-12-18 | LITS | Lite Strategy, Inc. | Schornstein Alexander | 10% owner | SELL | $1.37 | 690,611 | $946,137 | 3,674,862 |
| 2025-12-22 15:38 | 2025-12-19 | IMNM | Immunome Inc. | SIEGALL CLAY B | Director, Officer | BUY | $20.48 | 7,278 | $149,053 | 860,525 |
| 2025-12-23 04:48 | 2025-12-22 | PGEN | PRECIGEN, INC. | KIRK RANDAL J | Director, 10% owner | SELL | $4.18 | 1,900,036 | $7,942,150 | 4,598,044 |
| 2025-12-20 00:15 | 2025-12-18 | VTYX | Ventyx Biosciences, Inc. | Mohan Raju | Director, Officer | OPT+S | $7.72 | 47,345 | $365,461 | 2,372,863 |
| 2025-12-20 00:15 | 2025-12-18 | VTYX | Ventyx Biosciences, Inc. | Nuss John | Officer | OPT+S | $7.72 | 12,675 | $97,840 | 489,481 |
| 2025-12-20 01:24 | 2025-12-17 | RPRX | Royalty Pharma plc | Lloyd George W. | Officer | SELL | $38.55 | 110,000 | $4,240,335 | 0 |
| 2025-12-19 14:05 | 2025-12-18 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $12.62 | 4,100 | $51,742 | 5,592,202 |
| 2025-12-20 01:38 | 2025-12-19 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer | OPT+S | $30.61 | 7,000 | $214,293 | 1,518 |
| 2025-12-20 01:00 | 2025-12-17 | ADTX | Aditxt Inc. | Brady Brian Michael | Director | SELL | $1.75 | 1 | $2 | 3 |
| 2025-12-20 03:21 | 2025-12-17 | HYPD | HYPERION DEFI, INC. | Walters Happy David | Director | BUY | $3.02 | 61,930 | $187,152 | 111,930 |
| 2025-12-20 04:00 | 2025-12-17 | MNKD | MANNKIND CORP | Castagna Michael | Director, Officer | OPT+S | $6.01 | 65,804 | $395,482 | 2,504,792 |
| 2025-12-20 05:04 | 2025-12-17 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Director, Officer | OPT+S | $23.09 | 26,831 | $619,528 | 18,869,229 |
| 2025-12-20 00:05 | 2025-12-17 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $40.37 | 2,735 | $110,412 | 374,530 |
| 2025-12-20 00:05 | 2025-12-17 | PVLA | PALVELLA THERAPEUTICS, INC. | Goin Kathleen | Officer | OPT+S | $96.47 | 4,302 | $415,023 | 0 |
| 2025-12-19 15:00 | 2025-12-17 | RNXT | RenovoRx, Inc. | Bagai Shaun | Director, Officer | BUY | $0.85 | 5,000 | $4,262 | 335,040 |
| 2025-12-20 00:15 | 2025-12-18 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $69.73 | 2,000 | $139,460 | 0 |
| 2025-12-20 02:56 | 2025-12-17 | ARWR | Arrowhead Pharmaceuticals Inc. | Anzalone Christopher Richard | Director, Officer | SELL | $64.04 | 85,000 | $5,443,460 | 3,831,957 |
| 2025-12-20 00:30 | 2025-12-18 | KURA | Kura Oncology, Inc. | Burrows Francis | Officer | OPT+S | $9.78 | 23,726 | $231,931 | 33,735 |
| 2025-12-20 01:17 | 2025-12-19 | XERS | Xeris Biopharma Holdings, Inc. | JOHNSON JOHN | Director | SELL | $7.22 | 135,400 | $977,019 | 698,083 |
| 2025-12-20 05:30 | 2025-12-18 | CRMD | CorMedix Inc. | Todisco Joseph | Director, Officer | OPT+S | $12.00 | 30,000 | $360,000 | 509,496 |
| 2025-12-20 03:24 | 2025-12-17 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Director | SELL | $44.49 | 1,875 | $83,428 | 3,595,011 |
| 2025-12-20 00:05 | 2025-12-18 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Bhatt Padmanabh P. | Officer | OPT+S | $44.44 | 710 | $31,552 | 14,508 |
| 2025-12-20 05:00 | 2025-12-19 | TYRA | Tyra Biosciences, Inc. | MORE ROBERT J | Director | SELL | $25.00 | 10,000 | $250,000 | 3,823,425 |
| 2025-12-19 23:43 | 2025-12-18 | MNPR | Monopar Therapeutics | KLAUSNER ARTHUR J | Director | SELL | $67.15 | 5,121 | $343,889 | 8,762 |
| 2025-12-19 19:00 | 2025-12-17 | HYPD | HYPERION DEFI, INC. | GELTZEILER MICHAEL S | Director | BUY | $3.01 | 30,000 | $90,210 | 88,015 |
| 2025-12-20 01:00 | 2025-12-19 | SVRA | Savara Inc | RAMSAY DAVID A | Director | SELL | $6.06 | 20,000 | $121,220 | 2,533,642 |
| 2025-12-20 00:08 | 2025-12-17 | GALT | GALECTIN THERAPEUTICS INC | LEWIS JOEL | Director, Officer | OPT+S | $7.06 | 7,829 | $55,241 | 832,592 |
| 2025-12-20 00:06 | 2025-12-17 | GALT | GALECTIN THERAPEUTICS INC | Jamil Khurram | Officer | OPT+S | $7.04 | 19,442 | $136,872 | 0 |
| 2025-12-20 00:05 | 2025-12-17 | GALT | GALECTIN THERAPEUTICS INC | Shlevin Harold H. | Director | OPT+S | $7.04 | 24,499 | $172,424 | 6,500 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.